Parexel

Icon acquires Firecrest Clinical, adding portal technology to boost site quality while reducing errors and costs

Monday, July 25, 2011 08:02 AM

As large pharmaceutical companies scrutinize the pack of mid- and top-tier CROs to determine who wins the coveted strategic-partnership agreements, there’s a mad scramble among CROs to differentiate themselves from one another and stand out as efficient, high quality, exciting and deserving.

More... »

Strategic partnerships: a good deal for CROs, or just a cost-cutting measure by big pharma?

Monday, June 13, 2011 08:01 AM

Strategic partnerships with the top 20 pharma companies are what most sizable CROs dream of these days.

More... »

Pfizer chooses Icon and Parexel as its two strategic outsourcing partners in 5-year deals

Monday, June 6, 2011 10:23 AM

Strategic partnerships with large pharma recently have become the holy grail among CROs. And two have been awarded by Pfizer, the largest drug maker in the world.

More... »

Pfizer strategically partners with Icon, Parexel

Thursday, May 26, 2011 11:53 AM

Pfizer today doled out two large strategic partnership agreements, which have become the brass ring for which most CROs medium and large are jockeying.

More... »

Perceptive survey shows most CRAs use a CTMS

Friday, May 20, 2011 11:00 AM

Perceptive Informatics, an eClinical solutions provider and a subsidiary of Parexel, has results of a global survey conducted during its webinar entitled "Critical Tasks of Site Monitors: Using a CTMS to Improve Efficiency."

More... »

Trend shifts from phase I ‘healthy volunteers’

Tuesday, May 17, 2011 11:23 AM

Looking to stretch their research dollars beyond phase I safety determination and catch early glimpses of efficacy, sponsors and CROs are pursuing patient populations to provide those first signs, rather than depending on “healthy volunteers” for safety and then launching phase II trials.

More... »

Trend shifts away from phase I ‘healthy volunteers’

Monday, May 16, 2011 09:35 AM

Looking to stretch their research dollars beyond phase I safety determination and catch early glimpses of efficacy, sponsors and CROs are pursuing patient populations to provide those first signs, rather than depending on “healthy volunteers” for safety and then launching phase II trials.

More... »

Nautic purchase of Omnicare Clinical Research part of recent acquisition trend of mid-sized CROs

Thursday, May 5, 2011 01:22 PM

Omnicare Clinical Research, which had been part of publicly traded long-term care pharmacy company Omnicare Inc. since the late 1990s, was acquired by private equity firm Nautic Partners last week, making it one of several mid-sized CROs to be acquired in the last year.

More... »

Perceptive’s survey shows increasing interest in adaptive trial designs

Monday, April 25, 2011 12:55 PM

Perceptive Informatics, an eClinical solutions provider and a subsidiary of the Boston-based company Parexel, has results of a global survey conducted during its recent webinar entitled "Implementing Bayesian Response Adaptive Trials." The webinar was attended by over 300 professionals from the biopharmaceutical industry across a broad range of clinical, statistical and regulatory functions. Perceptive polled these professionals about their plans for the implementation of adaptive clinical trial designs.

More... »

Cytel names Jim Baker VP

Tuesday, March 22, 2011 12:00 PM

Cambridge, Mass.-based Cytel, a provider of clinical trial design and implementation services and software, has named Jim Baker vice president of clinical research services.

More... »